Literature DB >> 28117000

Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders.

Ewa Szczepanska-Sadowska1, Tymoteusz Zera1, Piotr Sosnowski2, Agnieszka Cudnoch-Jedrzejewska1, Anna Puszko3, Aleksandra Misicka3.   

Abstract

Vasopressin (AVP) and its receptors play a pivotal role in maintaining body homeostasis under physiological and pathophysiological conditions. As a consequence, the vasopressin system has emerged as an important target for both diagnostic and therapeutic applications in a number of medical conditions. Stoichiometric generation of AVP with copeptin, which is relatively accessible in the blood for measurements, makes copeptin a valuable surrogate of AVP. In this review, we present the regulation of release of AVP and activation of V1a, V1b, and V2 vasopressin receptors under physiological and pathological conditions. We make a survey of the role of AVP in: the regulation of the cardiovascular system; body fluid osmolality; natraemia; endocrine regulation; food intake; metabolism; circadian rhythmicity, immunological processes; and in the formation of learning, memory, cognition, and emotional and social behaviours. We also discuss the significance of the inappropriate functioning of the vasopressin system for: the development of cardiovascular diseases; disturbances of the water-electrolyte balance; energy metabolism; inflammatory processes; pain; neurogenic stress; memory disorders; depression; anxiety; autism; and schizophrenia. The structure and biological properties of peptide and non-peptide agonists and antagonists of V1a, V1b and V2 vasopressin receptors are presented and the potential use of copeptin and the current and likely indications for AVP agonists and antagonists in the diagnosis and therapeutics of multiple pathological conditions is discussed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Antidiuretic hormone; biomarkers; cardiovascular diseases; neuropeptides; psychiatric disorders; vaptans

Mesh:

Substances:

Year:  2017        PMID: 28117000     DOI: 10.2174/1389200218666170119145900

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  5 in total

Review 1.  Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation.

Authors:  Ewa Szczepanska-Sadowska; Agnieszka Wsol; Agnieszka Cudnoch-Jedrzejewska; Tymoteusz Żera
Journal:  Int J Mol Sci       Date:  2021-10-24       Impact factor: 5.923

Review 2.  Multiple Aspects of Inappropriate Action of Renin-Angiotensin, Vasopressin, and Oxytocin Systems in Neuropsychiatric and Neurodegenerative Diseases.

Authors:  Ewa Szczepanska-Sadowska; Agnieszka Wsol; Agnieszka Cudnoch-Jedrzejewska; Katarzyna Czarzasta; Tymoteusz Żera
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

Review 3.  Dysregulation of the Renin-Angiotensin System and the Vasopressinergic System Interactions in Cardiovascular Disorders.

Authors:  Ewa Szczepanska-Sadowska; Katarzyna Czarzasta; Agnieszka Cudnoch-Jedrzejewska
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 4.  Distinguishing Low and High Water Consumers-A Paradigm of Disease Risk.

Authors:  Lawrence E Armstrong; Colleen X Muñoz; Elizabeth M Armstrong
Journal:  Nutrients       Date:  2020-03-23       Impact factor: 5.717

5.  Interaction of Orexin A and Vasopressin in the Brain Plays a Role in Blood Pressure Regulation in WKY and SHR Rats.

Authors:  Stanisław Kowalewski; Katarzyna Czarzasta; Liana Puchalska; Ewa Szczepańska-Sadowska; Agnieszka Wsol; Agnieszka Cudnoch-Jędrzejewska
Journal:  Med Sci Monit       Date:  2020-10-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.